[{"id":"c39317e9-2ffe-4fe5-b487-781ec7511b8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02923180","created_at":"2021-01-18T14:21:11.868Z","updated_at":"2024-07-02T16:34:25.763Z","phase":"Phase 2","brief_title":"Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer","source_id_and_acronym":"NCT02923180","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1","pipe":" | ","alterations":" CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression","tags":["AR • PD-1 • LAG3 • CD276 • HAVCR2 • TNFRSF9 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/14/2017","start_date":" 02/14/2017","primary_txt":" Primary completion: 08/11/2020","primary_completion_date":" 08/11/2020","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-14"},{"id":"d2ef91c8-34da-461e-a797-3af5e0d2863c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05942456","created_at":"2023-07-12T15:08:57.209Z","updated_at":"2024-07-02T16:35:04.015Z","phase":"","brief_title":"Soluble B7-H3 as a Biomarker for Osteosarcoma","source_id_and_acronym":"NCT05942456","lead_sponsor":"Peking University People's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-14"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"746dce89-6a8e-4752-947c-6bc43ac4a8ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT04185038","created_at":"2021-01-18T20:24:04.775Z","updated_at":"2024-07-02T16:35:25.602Z","phase":"Phase 1","brief_title":"Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors","source_id_and_acronym":"NCT04185038","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCRI-CARB7H3(s)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 12/11/2019","start_date":" 12/11/2019","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2041","study_completion_date":" 05/01/2041","last_update_posted":"2023-12-20"},{"id":"38a37beb-d929-43d0-9890-ba3737cd0325","acronym":"","url":"https://clinicaltrials.gov/study/NCT06018363","created_at":"2023-08-30T14:09:03.022Z","updated_at":"2024-07-02T16:35:38.641Z","phase":"Phase 1/2","brief_title":"Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection","source_id_and_acronym":"NCT06018363","lead_sponsor":"Dushu Lake Hospital Affiliated to Soochow University","biomarkers":" IL6 • CD276 • IL10","pipe":" | ","alterations":" CD276 expression","tags":["IL6 • CD276 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e QH104"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-08-30"},{"id":"cc4fb18b-f792-4ae9-84d7-f106ddc4db2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04897321","created_at":"2021-05-21T11:52:50.695Z","updated_at":"2024-07-02T16:35:40.645Z","phase":"Phase 1","brief_title":"B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)","source_id_and_acronym":"NCT04897321","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-08-08"},{"id":"2ac1606a-0606-46ec-aac6-2458374bdc46","acronym":"","url":"https://clinicaltrials.gov/study/NCT05341492","created_at":"2022-04-22T13:53:34.891Z","updated_at":"2024-07-02T16:35:54.546Z","phase":"Phase 1","brief_title":"EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05341492","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • CD276","pipe":" | ","alterations":" EGFR expression • CD276 expression","tags":["EGFR • CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Undisclosed EGFR/B7H3 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-02-28"},{"id":"43102ae6-d1ea-4271-9690-90fe3e1581ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05731219","created_at":"2023-02-16T15:00:35.996Z","updated_at":"2024-07-02T16:35:55.393Z","phase":"Phase 1","brief_title":"UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05731219","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UTAA06"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/26/2022","start_date":" 09/26/2022","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 09/26/2025","study_completion_date":" 09/26/2025","last_update_posted":"2023-02-16"},{"id":"ecf3418c-bacc-4bfa-8dfc-631284d39661","acronym":"","url":"https://clinicaltrials.gov/study/NCT05722171","created_at":"2023-02-10T15:00:14.965Z","updated_at":"2024-07-02T16:35:55.834Z","phase":"Phase 1","brief_title":"Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05722171","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UTAA06"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 12/27/2023","primary_completion_date":" 12/27/2023","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2023-02-10"},{"id":"c56c0875-2077-4738-8cc2-b258916ee607","acronym":"","url":"https://clinicaltrials.gov/study/NCT03406949","created_at":"2021-01-18T16:48:34.491Z","updated_at":"2024-07-02T16:36:10.175Z","phase":"Phase 1","brief_title":"MGD009/MGA012 Combination in Relapsed/Refractory Cancer","source_id_and_acronym":"NCT03406949","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" PD-L1 expression • CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • obrindatamab (MGD009)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/27/2018","start_date":" 02/27/2018","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 04/27/2022","study_completion_date":" 04/27/2022","last_update_posted":"2022-05-19"},{"id":"22c4a7b3-005a-45aa-b942-f2db0868d6b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05323201","created_at":"2022-04-12T14:53:00.485Z","updated_at":"2024-07-02T16:36:13.151Z","phase":"Phase 1/2","brief_title":"Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer","source_id_and_acronym":"NCT05323201","lead_sponsor":"The Affiliated Hospital of Xuzhou Medical University","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • fhB7H3.CAR-Ts"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/10/2022","start_date":" 02/10/2022","primary_txt":" Primary completion: 02/10/2024","primary_completion_date":" 02/10/2024","study_txt":" Completion: 02/10/2027","study_completion_date":" 02/10/2027","last_update_posted":"2022-04-12"},{"id":"062d5143-0a78-494c-8bc5-54eadaa88e52","acronym":"","url":"https://clinicaltrials.gov/study/NCT02381314","created_at":"2021-01-18T11:20:48.335Z","updated_at":"2024-07-02T16:36:17.470Z","phase":"Phase 1","brief_title":"Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer","source_id_and_acronym":"NCT02381314","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • enoblituzumab (MGA271)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/26/2015","start_date":" 03/26/2015","primary_txt":" Primary completion: 11/09/2017","primary_completion_date":" 11/09/2017","study_txt":" Completion: 09/26/2018","study_completion_date":" 09/26/2018","last_update_posted":"2022-02-08"},{"id":"e895d13d-aaf1-4c85-81b2-e4cc448e1e94","acronym":"","url":"https://clinicaltrials.gov/study/NCT02982941","created_at":"2021-01-18T14:40:26.657Z","updated_at":"2024-07-02T16:36:17.394Z","phase":"Phase 1","brief_title":"Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors","source_id_and_acronym":"NCT02982941","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enoblituzumab (MGA271)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 05/22/2019","study_completion_date":" 05/22/2019","last_update_posted":"2022-02-08"},{"id":"faed0dd2-a4f9-464d-8199-fe65794a9804","acronym":"","url":"https://clinicaltrials.gov/study/NCT05211557","created_at":"2022-01-29T18:05:02.809Z","updated_at":"2024-07-02T16:36:17.869Z","phase":"Phase 1/2","brief_title":"Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer","source_id_and_acronym":"NCT05211557","lead_sponsor":"The Affiliated Hospital of Xuzhou Medical University","biomarkers":" CD276 • MUC16","pipe":" | ","alterations":" CD276 expression","tags":["CD276 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fhB7H3.CAR-Ts"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2022-01-27"},{"id":"c4881a68-0c3e-4386-9ca0-2ec5ff9fb456","acronym":"CAR-T","url":"https://clinicaltrials.gov/study/NCT05143151","created_at":"2021-12-03T18:53:48.505Z","updated_at":"2024-07-02T16:36:19.866Z","phase":"Phase 1/2","brief_title":"CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05143151 - CAR-T","lead_sponsor":"Shenzhen University General Hospital","biomarkers":" CD276 • BRCA","pipe":" | ","alterations":" CD276 expression","tags":["CD276 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/01/2021","start_date":" 07/01/2021","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2021-12-03"},{"id":"6dbe45e6-1246-42ed-ac2a-33333a3bb5df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02475213","created_at":"2021-01-18T11:55:04.422Z","updated_at":"2024-07-02T16:36:23.857Z","phase":"Phase 1","brief_title":"Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer","source_id_and_acronym":"NCT02475213","lead_sponsor":"MacroGenics","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Zynyz (retifanlimab-dlwr) • enoblituzumab (MGA271)"],"overall_status":"Completed","enrollment":" Enrollment 145","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 08/18/2021","primary_completion_date":" 08/18/2021","study_txt":" Completion: 08/18/2021","study_completion_date":" 08/18/2021","last_update_posted":"2021-09-28"},{"id":"6723422f-b2f2-4eaf-9e70-791a4494fab0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04864821","created_at":"2021-04-29T12:55:41.176Z","updated_at":"2024-07-02T16:36:30.616Z","phase":"Phase 1","brief_title":"Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor","source_id_and_acronym":"NCT04864821","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAA6-CAR-T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/14/2021","start_date":" 05/14/2021","primary_txt":" Primary completion: 05/14/2022","primary_completion_date":" 05/14/2022","study_txt":" Completion: 05/14/2023","study_completion_date":" 05/14/2023","last_update_posted":"2021-05-06"}]